Factors | No. of patients | OS | RFS | ||
---|---|---|---|---|---|
3-year OS (%) | p | 3-year RFS (%) | p | ||
Age | Â | Â | Â | Â | Â |
 < 55 years | 55 | 77% | 0.075 | 74% | 0.0291* |
 ≥ 55 years | 51 | 74% |  | 64% |  |
Clinical 8th AJCC stage | Â | Â | Â | Â | Â |
 0 | 10 | 100% | 0.0028* | 90% | 0.0062* |
 I | 80 | 75% |  | 70% |  |
 II | 14 | 50% |  | 43% |  |
 III | 2 | 100% |  | 100% |  |
Clinical T stage | Â | Â | Â | Â | Â |
 Tis | 11 | 100% | 0.0055* | 91% | 0.0125* |
 T1a | 79 | 76% |  | 70% |  |
 T1b | 16 | 56% |  | 50% |  |
Clinical N stage | Â | Â | Â | Â | Â |
 N0 | 97 | 75% | 0.47 | 70% | 0.49 |
 N1 | 7 | 71% |  | 57% |  |
 N2 | 2 | 100% |  | 100% |  |
Tumor grade | Â | Â | Â | Â | Â |
 Grade 0 (Tis) | 13 | 92% | 0.486 | 92% | 0.05* |
 Grade 1 | 8 | 63% |  | 63% |  |
 Grade 2 | 78 | 75% |  | 66% |  |
 Grade 3 | 7 | 86% |  | 86% |  |
Primary tumor location | Â | Â | Â | Â | Â |
 Upper | 21 | 76% | 0.0343* | 71% | 0.075 |
 Middle | 53 | 65% |  | 60% |  |
 Lower | 32 | 91% |  | 84% |  |
Pathologic 8th AJCC stage | Â | Â | Â | Â | Â |
 0 (Tis) | 17 | 94% | 0.198 | 94% | 0.249 |
 IA | 3 | 67% |  | 67% |  |
 IB | 86 | 72% |  | 65% |  |
Pathologic 8th AJCC T stage | Â | Â | Â | Â | Â |
 0 | 17 | 94% | 0.193 | 94 | 0.25 |
 T1a | 34 | 78% |  | 69 |  |
 T1b | 55 | 68% |  | 63 |  |
R0 resection | Â | Â | Â | Â | Â |
 Yes | 99 | 75% | 0.438 | 69% | 0.754* |
 No | 7 | 83% |  | 86% |  |
Procedure | Â | Â | Â | Â | Â |
 Endoscopic submucosal dissection | 25 | 87% | 0.118 | 83% | 0.085 |
 Esophagectomy | 81 | 72% |  | 66% |  |
Synchronous H&N cancer | Â | Â | Â | Â | Â |
 No | 53 | 82% | 0.593 | 77% | 0.494 |
 Yes | 53 | 69% |  | 63% |  |
Metachronous H&N cancer | Â | Â | Â | Â | Â |
 No | 87 | 73% | 0.471 | 68% | 0.605 |
 Yes | 19 | 79% |  | 74% |  |